Journey Medical Q3 EPS Forecast Lowered by HC Wainwright

Journey Medical Corporation (NASDAQ:DERM) – Research analysts at HC Wainwright decreased their Q3 2026 earnings estimates for Journey Medical in a note issued to investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.01 per share for the quarter, down from their prior estimate of $0.03. The consensus estimate for Journey Medical’s current full-year earnings is $0.17 per share. HC Wainwright also issued estimates for Journey Medical’s Q4 2026 earnings at $0.02 EPS, FY2027 earnings at $1.07 EPS, FY2028 earnings at $1.66 EPS, FY2029 earnings at $1.81 EPS and FY2030 earnings at $1.92 EPS.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. Journey Medical had a negative net margin of 8.95% and a negative return on equity of 20.67%. The firm had revenue of $18.51 million for the quarter, compared to analyst estimates of $18.36 million.

Several other equities research analysts have also issued reports on the stock. B. Riley Financial reissued a “buy” rating and set a $15.00 target price (up from $12.00) on shares of Journey Medical in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Journey Medical in a report on Friday, July 17th. Finally, Wall Street Zen raised Journey Medical from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $14.00.

Journey Medical Stock Up 3.4%

Shares of DERM stock opened at $6.65 on Friday. The stock has a market cap of $183.07 million, a P/E ratio of -30.23 and a beta of 1.08. Journey Medical has a twelve month low of $4.31 and a twelve month high of $9.56. The stock has a 50 day moving average of $6.59 and a 200 day moving average of $6.61. The company has a current ratio of 1.72, a quick ratio of 1.47 and a debt-to-equity ratio of 0.74.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Journey Medical during the 1st quarter worth about $110,000. Geode Capital Management LLC grew its position in shares of Journey Medical by 130.7% during the second quarter. Geode Capital Management LLC now owns 262,353 shares of the company’s stock worth $1,884,000 after buying an additional 148,612 shares in the last quarter. Creative Planning grew its position in shares of Journey Medical by 178.5% during the second quarter. Creative Planning now owns 32,764 shares of the company’s stock worth $235,000 after buying an additional 21,000 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Journey Medical during the second quarter worth approximately $41,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Journey Medical during the second quarter worth approximately $103,000. 7.25% of the stock is owned by institutional investors and hedge funds.

Key Journey Medical News

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Journey Medical reported a loss of $0.01 per share versus the $0.02 consensus loss, while revenue of $18.51 million topped estimates of $18.36 million. The earnings beat suggests better-than-expected operating performance. Journey Medical Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Emrosi momentum remained strong: Management highlighted a 20% sequential increase for Emrosi, which reached $8.1 million, along with 38% high-quality coverage. The company also signaled continued average selling price gains in the second half of 2026, supporting the growth outlook. Journey Medical Signals Continued ASP Gains
• Positive Sentiment: B. Riley raised its price target: The firm reaffirmed a “buy” rating and increased its target to $15 from $12, implying substantial potential upside from the stock’s recent $6.65 level. This reinforces the bullish view that Emrosi and the company’s dermatology portfolio can drive future growth.
• Neutral Sentiment: Long-term profitability remains a key catalyst: HC Wainwright still projects positive EPS from 2027 onward, including $1.07 in 2027 and $1.66 in 2028, but the estimates are now below its prior forecasts. Investors will likely focus on whether improving product sales can translate into sustained profitability.
• Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: Q3 2026 EPS was reduced to $0.01 from $0.03 and Q4 to $0.02 from $0.07. Estimates for fiscal 2027 through 2030 were also lowered, including 2030 EPS to $1.92 from $1.98. The cuts indicate expectations for slower near-term earnings growth and are the primary bearish factor in the news flow.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.